Yulia Lyuboslavsky
Adult Health · Austin, TXNPI 1215254024
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $22,050 of the $36,141 with a category attached, or 61.0%. AbbVie accounts for 80.9% of it on its own, with 28 other manufacturers making up the rest. Among adult health clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 664 payments — averaging $54.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$29K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
- Johnson & Johnson$541
- Bristol Myers Squibb$365
- Janssen Scientific Affairs, LLC$354
- Novo Nordisk$313
- plus $3K from 23 others
What the payments were for
- Speaking & faculty fees$22,05061%
- Travel & lodging$2,1136%
- Food & beverage$11,86233%
- Education$1150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 271 | $29,255 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 189 | $2,117 |
| Johnson & Johnson | 23 | $541 |
| Bristol Myers Squibb | 20 | $365 |
| Janssen Scientific Affairs, LLC | 3 | $354 |
| Novo Nordisk | 4 | $313 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $287 |
| Medtronic | 3 | $265 |
| Ardelyx, Inc. | 13 | $262 |
| Nestle Healthcare Nutrition Inc. | 15 | $244 |
| Sanofi | 9 | $239 |
| Redhill Biopharma Inc. | 18 | $230 |
| Daiichi Sankyo Inc. | 14 | $226 |
| Celltrion USA Inc. | 13 | $196 |
| Enterra Medical, Inc. | 1 | $154 |
| Lilly USA, LLC | 6 | $133 |
| QOL Medical, LLC | 5 | $130 |
| Intercept Pharmaceuticals, Inc. | 8 | $127 |
| Merck | 5 | $112 |
| Aimmune Therapeutics, Inc. | 6 | $97 |
| Madrigal Pharmaceuticals | 4 | $88 |
| Ironwood Pharmaceuticals, Inc | 4 | $87 |
| Pfizer | 5 | $75 |
| Gilead | 3 | $61 |
| Ipsen Biopharmaceuticals, Inc | 3 | $61 |
| Regeneron Healthcare Solutions, Inc. | 1 | $38 |
| Ferring Pharmaceuticals Inc. | 2 | $30 |
| Braintree Laboratories, Inc. | 2 | $29 |
| Organon | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$36,141 in reported general payments places this provider in the 95th percentile of 933 adult health providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 14 | $34,569 |
| XifaxanRifaximin | 12 | $34,535 |
| LinzessLinaclotide | 35 | $25,214 |
| TrulancePlecanatide | 16 | $11,782 |
| PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C | 53 | $7,165 |
| Mesalamine ErMesalamine | 15 | $4,887 |
| Rabeprazole Sodium | 60 | $1,954 |
| Lubiprostone | 17 | $1,584 |
| Pantoprazole Sodium | 130 | $1,545 |
| SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag | 11 | $1,347 |
| Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg | 45 | $1,168 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 17 | $1,016 |
| Omeprazole | 93 | $855 |
| Dicyclomine Hcl | 52 | $852 |
| Budesonide EcBudesonide | 14 | $456 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess | $29,255 | $59,78249 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance, Plenvu | $2,117 | $53,48281 claims |
| Braintree Laboratories, Inc.Suflave | $29 | $1,34711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 933 adult health providers in Texas.
Other adult health in Austin
- Elizabeth Wedberg SivamAustin$71K
- Meghan MurphyAustin$29K
- Nicole BuschAustin$28K
- Marni MartinezAustin$14K
- Melani DayalAustin$13K
- Laura CalaisAustin$12K
- Shane ConcepcionAustin$10K
- Dorothy DarbyAustin$9K
- Lauren KissockAustin$9K
- Sarah RayAustin$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.